Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11890922 | 1.00 | LMNA (0.31) | LMNAL3MBTL1AMY1AMGAM | |
| SCHEMBL12748956 | 1.00 | LMNA (0.31) | LMNAL3MBTL1AMY1AMGAM | |
| SCHEMBL11890878 | 0.86 | L3MBTL1 (0.45) | L3MBTL1 | |
| SCHEMBL11890934 | 0.86 | L3MBTL1 (0.45) | L3MBTL1 | |
| SCHEMBL11890955 | 0.86 | L3MBTL1 (0.45) | L3MBTL1 | |
| SCHEMBL11890833 | 0.86 | L3MBTL1 (0.45) | L3MBTL1 | |
| SCHEMBL11890945 | 0.86 | L3MBTL1 (0.45) | L3MBTL1 | |
| SCHEMBL19387816 | 0.84 | TDP1 (0.34) | LMNAL3MBTL1AMY1AMGAM | |
| SCHEMBL14683438 | 0.84 | AMY1A (0.33) | LMNAL3MBTL1AMY1A | |
| SCHEMBL11890950 | 0.84 | AMY1A (0.32) | AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | F2R, C1R, PRSS1 | LMNA 1975/4885L3MBTL1 3434/4885AMY1A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.